TITLE

The safety of combining angiotensin-converting- enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis

AUTHOR(S)
McAlister, Finlay A.; Jianguo Zhang; Tonelli, Marcello; Klarenbach, Scott; Manns, Braden J.; Hemmelgarn, Brenda R.
PUB. DATE
April 2011
SOURCE
CMAJ: Canadian Medical Association Journal;4/5/2011, Vol. 183 Issue 6, p655
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The risks associated with using an angiotensin-converting-enzyme (ACE) inhibitor and an angiotensin-receptor blocker together are unclear. This study was designed to determine the safety of combination therapy with these two drugs in clinical practice. Methods: We conducted a population-based longitudinal analysis using linked administrative and laboratory data for elderly patients who were new users of an ACE inhibitor, an angiotensin-receptor blocker or a combination of both medications between May 1, 2002, and Dec. 31, 2006. We compared outcomes in patients given combination therapy versus patients given monotherapy using Cox proportional hazards analyses with adjustment for baseline characteristics. Results: Of the 32 312 new users of either medication (mean age 76.1 years, median creatinine level 92 µmol/L), 1750 (5.4%) received combination therapy. However, 1512 (86.4%) of the patients who were given combination therapy did not have trial-established indications such as heart failure or proteinuria. Renal dysfunction was more common among patients given combination therapy (5.2 [95% confidence interval (CI) 3.4 to 7.9] events per 1000 patients per month) than among patients given monotherapy (2.4 [95% CI 2.2 to 2.7] events per 1000 patients per month) (adjusted hazard ratio [HR] 2.36, 95% CI 1.51 to 3.71). Hyperkalemia was also more common among patients given combination therapy (2.5 [95% CI 1.4 to 4.3] events per 1000 patients per month) than among patients given monotherapy (0.9 [95% CI 0.8 to 1.0] events per 1000 patients per month) (adjusted HR 2.42, 95% CI 1.36 to 4.32). Most patients took combination therapy for only a short time (median three months before at least one agent was stopped). Interpretation: Combination therapy was frequently prescribed for patients without established indications and was associated with an increased risk of adverse renal outcomes when compared with monotherapy. These results mirrored data from randomized controlled trials.
ACCESSION #
60157951

 

Related Articles

  • THE JUNE 2003 BARRY M. BRENNER COMGAN LECTURE The future of renoprotection: Frustration and promises. Schieppati, Arrigo; Remuzzi, Giuseppe // Kidney International;Dec2003, Vol. 64 Issue 6, p1947 

    Considers the prospects for renoprotection, which involves the blockade of angiotensin II with an angiotensin-converting enzyme inhibitor in order to slow the progressive loss of renal function. Growth of the global burden of end-stage renal disease; Mechanisms of progression of renal disease;...

  • Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension[sup 1]. Delles, Christian; Jacobi, Johannes; John, Stefan; Fleischmann, Ingrid; Schmieder, Roland E // Kidney International;Apr2002, Vol. 61 Issue 4, p1462 

    Background: Experimental data in humans on the contribution of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers to the nitric oxide system of the renal vasculature are inconsistent. Enalapril and eprosartan, alone and in combination, were used to determine...

  • The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study Szeto, Cheuk-Chun; Kwan, Bonnie Ching-Ha; Chow, Kai-Ming; Leung, Chi-Bon; Li, Philip Kam-Tao // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    Background: Laboratory research and previous study suggest that aliskiren, a direct renin inhibitor, has anti-proteinuric effects. We conducted a randomized crossover study to evaluate the anti-proteinuric effect of aliskiren in patients with immunoglobulin A (IgA) nephropathy. Methods: We...

  • Association of Blindness and Hearing Impairment with Mortality in a Cohort of Elderly Persons in a Rural Area. Agrawal, Nilesh; Kalaivani, M.; Gupta, Sanjeev K.; Misra, Puneet; Anand, K.; Pandav, Chandrakant S. // Indian Journal of Community Medicine;Jul2011, Vol. 36 Issue 3, p208 

    Background: Studies in developed nations have reported an association of blindness and hearing impairment with mortality in elderly persons. Objectives: To study the association of blindness and hearing impairment with mortality in a cohort of elderly persons in rural north India. Materials and...

  • Slowing the progression of renal failure. Praga, Manuel // Kidney International Supplement;May2002, Issue 80, p18 

    Slowing the progression of renal failure. In recent years several multicentric prospective studies have demonstrated the efficacy of some therapeutic measures to slow the progression of renal diseases. Inhibition of renin-angiotensin system (RAS) both by ACE inhibitors (ACEI) and angiotensin II...

  • Association of Blood Pressure with the Start of Renal Replacement Therapy in Elderly Compared with Young Patients Receiving Predialysis Care. de Goeij, Moniek C.M.; de Jager, Dinanda J.; Grootendorst, Diana C.; Voormolen, Nora; Sijpkens, Yvo W.J.; van Dijk, Sandra; Hoogeveen, Ellen K.; Kooman, Jeroen P.; Boeschoten, Elisabeth W.; Dekker, Friedo W.; Halbesma, Nynke // American Journal of Hypertension;Nov2012, Vol. 25 Issue 11, p1175 

    BackgroundIn the growing elderly predialysis population, little is known about the effect of identified risk factors on the progression to end-stage renal disease. Therefore, we investigated the association of systolic (SBP) and diastolic blood pressure (DBP) with the start of renal replacement...

  • Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Iseki, Kunitoshi; Arima, Hisatomi; Kohagura, Kentaro; Komiya, Ichiro; Ueda, Shinichiro; Tokuyama, Kiyoyuki; Shiohira, Yoshiki; Uehara, Hajime; Toma, Shigeki // Nephrology Dialysis Transplantation;Jun2013, Vol. 28 Issue 6, p1579 

    Background Hypertension is a major risk factor for death and cardiovascular disease (CVD) in patients undergoing chronic haemodialysis (HD), but there is uncertainty surrounding the effects of blood pressure (BP) lowering on this high-risk patient group. Methods In a multicenter, prospective,...

  • Prevention of Recurrent Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Systematic Review and Meta-Analysis of Randomized Trials. Bhuriya, Rohit; Singh, Mukesh; Sethi, Ankur; Molnar, Janos; Bahekar, Amol; Singh, Param Puneet; Khosla, Sandeep; Arora, Rohit // Journal of Cardiovascular Pharmacology & Therapeutics;Jun2011, Vol. 16 Issue 2, p178 

    Background: Controversy persists regarding the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the prevention of recurrent atrial fibrillation (AF). We performed a meta-analysis of randomized controlled trials (RCTs), not designed a priori...

  • THE AUTHORS REPLY. Korn, Edward L.; Graubard, Barry I.; Midthune, Douglas // American Journal of Epidemiology;1997, Vol. 146 Issue 6, p529 

    A response from the authors of the article "Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale" in the 1997 issue is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics